Notably, somatic TP53 PVs are most frequent in breast cancer, reaching incidence rates of 28–37% [27, 28], and are especially frequent in the HER2 + than in the HR + subtype (72%, and 12–29%, respectively) [27]. Here, ERBB2 is linked to breast cancer.